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METHOD AND KIT FOR DETERMINATION
OF PROSTACYCLIN IN PLASMA

and Class IV patients Who do not respond to conventional

therapy. (Krishnan, U. Indian J. Pediatn 2000, 67, 523-527;
Nauser, T. D., Stites, S. W. Am. Fam. Physician 2001, 63,

RELATED APPLICATIONS

1789-1798). There is no set dose of prostacyclin for PPH and

the starting dose varies betWeen 4-8 ng/kg/min. Following the
initiation of intravenous prostacyclin, most patients require

This application claims the bene?t of provisional applica
tion 60/396,122, ?led Jul. 17, 2002, Which is incorporated
herein in its entirety.

an automatic dose increase of 2 ng/kg/min every tWo Weeks
until the rate of administration reaches 20 ng/kg/min. Further
dose increase of 0.5 to 1 ng/kg/min per Week is needed only
upon the return of symptoms. Common side effects of intra

This invention Was made With government support pro

vided by The National Institutes of Health.
FIELD OF THE INVENTION

venous prostacyclin include ?ushing, muscle pain, and

The invention relates generally to methods of determining
the level of pro stacyclin in plasma using the conjugates. More
particularly, the invention relates to a single step immunoas
say for detection of the level of 6-keto-prostaglandin F1,
Which directly correlates to the level of prostacyclin in

determining the optimal level of plasma prostacyclin for an
individual patient.

abdominal cramps and these symptoms are not necessarily
dose dependent. Thus, a method to quantify and correlate the
plasma levels of prostacyclin With the onset of the untoWard
side effects or functional improvement Would be useful in

plasma.
20

BACKGROUND OF THE INVENTION

unstable With a half-life of only 60 minutes in plasma and 2-3
minutes in buffer. The immediate and stable product of

Primary Pulmonary Hypertension (PPH) is a rare disease

of the pulmonary vasculature, resulting in abnormally high
pressure in the pulmonary artery, right ventricular failure, and

hydrolysis of prostacyclin, 6-Keto-Prostaglandin Fla
25

death. While the pathogenesis of PPH is not clearly under
stood, the increased pulmonary vascular resistance observed
is attributed to three main factors: 1) vasoconstriction, 2)
thickening of the vessel Wall due to vascular remodeling, and

3) in situ thrombosis. (Archer, S., Rich, S. Circulation 2000,
102, 2781-2791; Rich, S. Curr. Treat Options. Cardiovasc.
Med. 2000, 2, 135-140). There is no cure for PPH and the
treatment options are limited. (Naeije, R.,Vachiery, J. L. Clin.
Chest Med. 2001, 22, 517-527). The survival rate is less than
a year in patients presented With NeWYork Heart Association

(6-keto-PGFla), is quanti?able and can be used as a surrogate

marker of the level of plasma prostacyclin. The detection
method for prostacyclin or its breakdoWn product has to be
extremely sensitive and accurate since either molecule is
30

present in very loW amounts (pg/mL) in the body. Moreover,
the existing methods are time consuming mainly due to the

necessity to extract 6-keto-PGF1G from biological samples.
(Schramm, W., Smith, R. H., Jackson, T. M., Craig, P. A.,
Grates, H. E., and Minton, L. L. Clinical Chem. 1990, 36,
35

Functional Class IV symptoms. Although lung transplanta

509-514; Tonai T.,Y., K.,Yano, T., Hayashi,Y.,Yamamoto, S.,
Yamashita, K., and MiyaZaki, H. Biochim. Biophys. Acta
1985, 836, 335-343). Thus there is a need for a rapid and
sensitive detection method for prostacyclin. The present

tion is a possible treatment option, there are obvious draW
backs such as shortage of donor organs and chronic rejection
as Well as the possibility of infection. (Franke, U., Wiebe, K.,

Harringer, W., Franke, T., WittWer, T., Wahlers, T., Haverich,

A method to quantify the plasma levels of prostacyclin
Would be useful in determining the optimal level of plasma
prostacyclin for an individual patient. Prostacyclin is very

40

invention provides a single-step, solid phase immunoassay
for 6-keto-PGF1a using the bioluminescent protein aequorin.

A. Eur J. Cardiothorac. Surg. 2000, 18, 447-452). Long term

SUMMARY OF THE INVENTION

intravenous treatment With epopro stenol (also knoWn as pros

tacyclin or PGI2) has greatly increased the survival rate.

Prostacyclin or PGI2 (Prostaglandin I2) is a major
cyclooxygenase metabolite of arachidonic acid, and is mainly
produced by vascular endothelial cells. Prostacyclin is a pros

In one aspect of the invention there is provided an assay for
45

determining amount of prostacyclin in a plasma sample com

prising:

taglandin, Which occurs along With other eicosanoids like
thromboxanes and leukotrienes. Prostacyclin is a potent

(1) providing a plasma sample on a surface coated With an

vasodilator With platelet-inhibitory, anti-proliferative and
?brinolytic activities. (Moncada, S., Vane, J. R. Pharmaco

(2) incubating the plasma sample With an effective amount
of an anti-6-keto-PGFla primary antibody, a secondary

anti-immunoglobulin antibody;
50

logical Rev. 1979, 30).

anti-6-keto-PGF1a antibody and 6-keto-PGFla-ae

The exact levels of prostacyclin in human plasma are

quorin conjugate;

unknoWn, hoWever like mo st eicosanoids it occurs in very loW

(3) removing any unbound primary antibody and 6-keto

amounts (pg/mL). Thromboxane B2 (metabolite of throm
boxane A2, a vasoconstrictor) and its metabolites occur in

very loW amounts like 1-10 pg/mL in plasma. Leukotrienes
generally function as vasoconstrictors and bronchoconstric
tors and occur in varying amounts in plasma and urine. Leu
kotriene B4 occurs betWeen 50 pg/mL-50 ng/mL, leukotriene
E4 occurs betWeen 80 pg/mL-1000 ng/mg of creatinine. Pros
taglandin F20‘ concentrations are found betWeen 10 pg/mL

55

sample With amount of prostacylin Within the plasma

sample.
60

In a preferred embodiment of this aspect of the invention,
the assay is performed in a microtiter format. Preferably, the
secondary antibody is coated onto a surface and exposed to

the plasma sample, primary antibody and 6-keto-PGFl-ae

100 pg/mL, prostaglandin D2 is generally found at 5 pg/mL

quorin conjugate.

500 pg/mL, and prostaglandin Fla occurs at 1 ng/mL-100

ng/mL.
Currently intravenous epoprostenol is indicated for the

PGFla-aequorin conjugate folloWing incubation; and
(4) measuring and correlating light intensity of the plasma

In another aspect of the invention there is provided a

chronic treatment of primary pulmonary hypertension (PPH)

method of determining an appropriate dose of prostaglandin
for the treatment of primary pulmonary hypertension in a

in NeW York Heart Association (NYHA) functional Class III

patient comprising

65
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3
(1) providing a plasma sample from the patient;

trom. 1985, 12, 399-404; and Maclouf, 1., Pradel, M.,
Pradelles, P. and Dray, F. Biochim. Biophys. Acta 1976, 431,

(2) incubating the plasma sample With an effective amount

139-146.

of anti-6-keto-PGF 1 primary antibody, a secondary anti

6-keto-PGFl antibody, a 6-keto-PGF1-aequorin conju
gate;
(3) removing any unbound primary antibody and conjugate
from the plasma sample folloWing incubation;

In contrast, the present invention provides a sensitive biolu
minescent immunoassay for 6-keto-PGF la Where the plasma

samples are analyZed directly Without requiring the extrac
tion of 6-keto-PGFla from plasma. This results in a simpler,
faster method for detection of this analyte in plasma samples.

(4) measuring and correlating amount of detected 6-keto
PGFl With the appropriate dosage of prostaglandin for

The present assay for 6-keto-PGFla is preferably performed
in a microtiter plate format using the photoprotein aequorin as
the label. Colorimetric and ?uorescent assays could possibly
suffer from background interference limiting their use in

the patient.
In another aspect of the invention there is provide a kit for

measuring amount of prostacyclin in plasma comprising
(1) a 6-keto-PGF1-aequorin conjugate;
(2) an anti-6-keto-PGFl primary antibody; and
(3) a secondary anti-6-keto-PGFl primary antibody coated

direct plasma analysis. Aequorin, hoWever, being a biolumi
nescent label has virtually no background associated With
aequorin is a highly sensitive label.
Aequorin has proved to be a highly sensitive label in the

plate.

development of binding assays for the determination of large
and small biomolecules. (Zenno, S., Inouye, S. Biochem.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shoWs the binder dilution curves obtained by incu

Biophys. Res. Commun. 1990, 171, 169-174; Christopoulos,
20

bating a volume of 100 ML of varying concentrations of

6-keto-PGF1a antibody and 6-keto-PGFla-aequorin conju
gates With secondary antibody coated plates. Data are an
average of three pointszthe standard deviation. (I) 1 :50 Con

jugate, (O) 1:100 Conjugate, (Q) 1:500 Conjugate.

25

FIG. 2 shoWs the dose-response curves for 6-keto-PGF1a

of an apoprotein (apoaequorin, 189 amino acid residues), a

generated by incubating varying concentrations of 6-keto
PGFla With 1><10_lo M conjugate and (I) 1:5000 dilution of
6-keto-PGF1a antibody, or (Q) 1:50,000 dilution of 6-keto
PGFla antibody and 1:10,000 dilution of 6-keto-PGF1a anti

30

chromophoric unit (coelenteraZine) and molecular oxygen.
Aequorin has three Ca2+ binding sites. When Ca2+ binds to
aequorin, it undergoes a conformational change that results in
the oxidation of coelenteraZine to coelenteramide and this

body With ( )1><10_9 M 6-keto-PGFla-AEQ conjugate. Data

produces CO2 and emits a ?ash of light at 469 nm. The

are an average of three pointsithe standard deviation.
FIG. 3 is a dose-response curve for 6-keto-PGF la obtained

by incubating 100 ML of 6-keto-PGFla antibody, 50 ML vol

T. K., and Galvan, B. Anal. Chem. 1996, 68, 3545-3550;
Zatta, P. F. J. Biochem. Biophys. Methods 1996, 32, 7-13;
Stults, N. L., Stocks, N. F., Riviera H., Gray 1., McCann R. O.,
O’Kane D., Cummings R. D., Cormier M. 1., and Smith D. F.
Biochemistry 1991,31, 1433-1438). The bioluminescent pro
tein aequorin is native to the jelly?sh Aequorea Victoria.
Aequorin is a bioluminescent photoprotein that is composed

bioluminescent signal produced by aequorin has virtually no
background signal and the quantum e?iciency is betWeen
35

ume of 1x10“10 M 6-keto-PGFla-AEQ conjugate and vary

1 1-17.5%, alloWing it to be detected doWn to attomole levels.

ing concentrations of 6-keto-PGFla. Data are an average of

(Stults, N. L., Stocks, N. F., Riviera H., Gray 1., McCann R.
O., O’Kane D., Cummings R. D., Cormier M. 1., and Smith D.

three pointszthe standard deviation.

F. Biochemistry 1991, 31, 1433-1438; Ramanathan, S.,

FIG. 4 is a dose-response curve for 6-keto-PGF1a in

plasma of a healthy person obtained by incubating 100 ML of
6-keto-PGF1a antibody, 50 ML volume of1><10_1O M 6-keto
PGF m-AEQ conjugate and varying concentrations of 6-keto

40

LeWis, 1. C., Kindy, M. S., and Daunert, S. Anal. Chim. Acta.
1998, 369, 181-189; Shimomura, O. Biol. Bull. 1995, 189,
1-5; LeWis, 1. C., LopeZ-Moya, 1. 1., and Daunert S. Biocon

jugate Chem. 2000, 11, 65-70).

PGFla in 1:200 diluted plasma. Data are an average of three

In the present invention a cysteine-free mutant of aequorin

pointszthe standard deviation.
45

DETAILED DESCRIPTION OF THE INVENTION

is preferred because it shoWs enhanced activity. LeWis, 1. C.,
LopeZ-Moya, 1. 1., and Daunert S. Bioconjugate Chem. 2000,
11, 65-70, incorporated herein in its entirety. HoWever, any
suitable aequorin may be used as a label in the present meth

ods and kits. Recombinant aequorin may be produced and
puri?ed for use in the present assay for 6-keto-PGFla. For

Various types of detection methods have been reported in

the literature for prostacyclin using its stable hydrolysis prod
uct, 6-keto-PGF 1w as a measure of prostacyclin levels. For 50

example, the compound 6-keto-PGFla may be conjugated to

example, the methods include radioimmunoassays, enZyme

pure aequorin by conventional covalent attachment to the free
amine groups of the lysine residues in aequorin. Aequorin
contains 15 lysine residues.
In developing the present assay, the effect of choosing
different initial ratios of analyte to the apoprotein on the

immunoassays, and detection using gas liquid chromatogra
phy-mass spectrometry (GLC-MS) or gas chromatography

selective ion monitoring (GC-SIM). (Tonai T., Y., K., Yano,
T., Hayashi, Y., Yamamoto, S., Yamashita, K., and MiyaZaki,

55

bioluminescence properties of the protein, and the binding
ability of an anti-6-keto-PGF1a antibody Was investigated.

H. Biochim. Biophys. Acta 1985, 836, 335-343; Fischer C, M.
C. Biomed. Mass Spectrom. 1985, 12, 399404; and Maclouf,
1., Pradel, M., Pradelles, P. and Dray, F. Biochim. Biophys.
Acta 1976, 431, 139-146. Radioimmunoassay is a highly
sensitive method but it has the disadvantages associated With
the use of radioactivity. Moreover, all the immunoassays or

Further, the effect of an antibody for 6-keto-PGF1a on the
luminescence signal Was evaluated. Based on the results, the
60

optimiZed for detection of the analyte in plasma. Several

chromatographic techniques reported for 6-keto-PGF 1w
require extraction of 6-keto-PGFla from plasma or plasma
samples making the process laborious and time consuming.

(Tonai T., Y., K., Yano, T., Hayashi, Y., Yamamoto, S.,
Yamashita, K., and MiyaZaki, H. Biochim. Biophys. Acta
1985, 836, 335-343; Fischer C, M. C. Biomed. Mass Spec

sensitive bioluminescent binding assay for 6-keto-PGF1a
described herein Was developed. The assay Was then further

plasma samples from PPH patients Were analyZed by using
them directly in the assay Without any extraction of 6-keto
65

PGFla.
In the present method, the detection and quanti?cation of
6-keto-PGF1a directly in a plasma sample Without extraction

US 7,659,078 B1
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of the prostaglandin is achieved using a 6-keto-PGFl anti

body and a 6-keto-PGF-aequorin conjugate. The plasma

Similarly, these conjugates can be used in assays to determine
the effects of the conjugated biomolecule on drug therapy, for

sample may be diluted, for example about 200-fold With an

example
Aequorin- or mutant aequorin-biomolecule conjugates

appropriate medium, such as deionized Water, and an effec

tive amount of antibody and prostaglandin-conjugate added.

prepared either through non-speci?c, site-speci?c or genetic

An effective amount of antibody to be used in the assay

conjugation can be used in the assays of the invention.
Aequorin mutants Which have a unique cysteine at amino acid
residue 69, 70, 74 or 76 (described in the examples) have been
developed. These amino acid residues are close to the sub

dependent upon the particular antibody used and is selected to
such that the light intensity generated thereWith is su?icient to
measure a signal above background, While keeping the

strate-binding site in aequorin and therefore, binding of anti

amount of available binding sites to a minimum. In general,

body to an analyte attached at any of these sites yields a
homogeneous change in bioluminescence. Such results Were

When the amount of antibody is increased, the sensitivity of
the assay is improved but the detection limit of the assay is
compromised. When a more diluted amount of antibody is

used, the dynamic range is narroWed and sensitivity is
reduced.

The amount of 6-keto-PGF-aequorin conjugate used in the
present assay depends upon the speci?c conjugate used and
can readily be determined by one of skill in the art. In general,
the concentration range of conjugate is about 0. l x l 0'10 to
about 9x10“ 1 0, preferably about 1x10“ 1 O.
In carrying out the present assay in a microtiter plate for

20

buffer, deioniZed Water, and/ or microtiter plates or other sur

faces pre-coated With the secondary antibody or for coating
With secondary antibody at the time of performing the assay.

mat, a plasma sample is obtained from a patient and applied to
a surface, such as a surface of a microtiter plate, that has been

precoated With a secondary antibody. An amount of anti-6

demonstrated With an aequorin-thyroxine conjugate, Where
the thyroxine is bound to the sulfhydryl of a unique cysteine
at position 71 of the aequorin molecule.
The present invention also contemplates kits for measuring
amount of prostacyclin in a plasma sample. Kits preferably
contain a primary antibody for 6-keto-PGF1a and a secondary
antibody and a 6-keto-PGFla-aequorin conjugate. Prefer
ably, the conjugate is a cysteine-free mutant of aequorin con
jugated to 6-keto-PGFla. The kit may also include assay

25

EXAMPLE 1

keto-PGFla primary antibody and anti-6-keto-PGFla-ae
quorin conjugate is then added to the plasma sample and the

Reagents used in the examples herein include: Luria Ber
tani (LB) broth and agar Were purchased from DIFCO Labo

mixture incubated in the dark for a period of time ranging
from about 1 to about 3 hours, preferably about 2 hours at

ratories (Detroit, Mich.). Sodium dodecyl sulfate (SDS),
sodium hydroxide, sodium chloride, calcium chloride,

room temperature. The surface is then Washed to remove

unbound primary antibody and conjugate, and the light inten
sity is determined and correlated With the amount of 6-keto
PGF la present in the sample, Which in turn directly correlates
With the amount of prostacyclin in the sample.
The determination of amount of prostacyclin in a sample
obtained from a patient may then be used to determine the
appropriate dosage of prostglandin to administer to a patient

bovine plasma albumin (B SA), kanamycin, ethylenediamine
tetra acetic acid (EDTA) disodium salt and 6-keto-Prostag
landin F la Were obtained from Sigma Laboratories (St. Louis,
35

purchased from Pierce (Rockford, Ill.). HQH, quatemiZed
polyethyleneimine anion exchanger Was purchased from Per

being treated for PPH, for example.
It has been ob served in the scienti?c literature that the drug,
Viagra®, available from P?zer Inc. is a potential candidate for

Septive Biosystems (Cambridge, Mass.). The anti-6-keto
40

therapy in patients suffering from PPH. Sayin et al., Can. J.
Cardiol., 2002, 18(6): 676-678. It has been demonstrated that
Viagra® acts as an inhibitor of the enZyme, phosphodi
esterase. Inhibition of this enZyme causes increase in levels of

Prostaglandin E la antibody and the 96-Well microtiter plates
coated With anti-sheep-IgG Were purchased from Assay

Designs Inc. (Ann Arbor, Mich.). Tris (hydroxymethyl)
amino methane (Tris) Was purchased from Research Organics
(Cleveland, Ohio). CoelenteraZine Was purchased from Bio
45

cGMP and cAMP, Which control groWth of the smooth
muscle cell layer that surrounds pulmonary arterioles. Prolif
eration of these smooth muscle cells has been linked With

synth International (Naperville, Ill.). Bradford assay kits
Were obtained from Bio-Rad Laboratories (Hercules, Calif.).
Patient samples as Well as control samples Were provided by
Dr. Michael Poon (Mount Sinai School of Medicine, NY).
All solutions Were prepared using deioniZed (Milli-Q Water

PPH. Prostacylin also acts as a dilator of smooth muscle cells

by increasing the levels of cyclic nucleotides. Furthermore, it

Mo.). N-hydroxysuccinimide (NHS) and l-Ethyl-3-(Dim
ethylaminopropyl) carbodiimide hydrochloride (EDC) Were

50

Puri?cation System, Millipore, Bedford, Mass.) distilled

has been found that phosphodiesterase inhibitor enhances

Water. All chemicals Were analytical reagent grade or better,

vasodilatory ef?cacy of prostacyclin. Thus, the effects of

With >95% purity and Were used as received.
Cell cultures Were groWn in an orbital shaker, Form a

Viagra® therapy on levels of prostacyclin in the blood can be

determined using the assay for 6-keto-prostaglandin,
described herein. Also, the appropriate dosage of Viagra®
can also be determined by application of the assay for 6-keto

Scienti?c (Marrietta, Ohio) and centrifuged using a Beckman
J2-MI centrifuge (Palo Alto, Calif.). The fractions Were lyo
philiZed using a VirTis Bench Top three freeZe dryer (Gar

prostaglandin, described herein.
The present invention also provides unique aequorin

Were made on MLX Microtiter Plate Luminometer Dynex

mutants that are suitable for conjugation to 6-keto protaglan

(Chantilly, Va.). For all the measurements four replicates

55

diner, N.Y.). Bioluminescence measurements for the assay

din F 1 for use in the above-described as says or for conjugation 60 Were performed and three of the closest Were selected. All

luminescence intensities reported are the average of three
replicates, and have been corrected for the contribution of the

to other biomolecules, such as those suspected of playing a

pathologicaal role in PPH, e.g., endothelin, angiotensin II,

background.

vasopressin, and neurotransmitter. These mutant aequorins
can be conjugated to the desired biomolecule to analyZe the
role of the biomolecule in PPH, to analyZe the metabolism of
the biomolecule, to determine any correlation of serum level

With physiological effect, or for drug design, for example.

65

Expression and Puri?cation of Apoaequorin: The plasmid
pSDl 10 containing the cysteine free mutant (mutant S) of
aequorin Was constructed and initially transformed in com

petent B. sublilis cells. For protocols for the expression and

US 7,659,078 B1
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puri?cation of apoaequorin and the conversion of apoae
quorin to the photoprotein, see Lewis, J. C., LopeZ-Moya, J.

With 6-keto-PGFla-aequorin conjugate and the 6-keto

J ., and Daunert S. Bioconjugale Chem. 2000, 11, 65-70,

antibody. The incubation and Washing steps Were performed

incorporated herein.
Conjugation of Aequorin to 6-keto-Prostaglandin Fla: A

in the same manner as previously described in the generation
of dose-response curve. The bioluminescence Was triggered

volume of 1 mL of 1x10“6 M. aequorin Was allowed to incu
bate With coelenteraZine for 3 h at 4° C. The N-hydroxysuc

and measured as described before.

PGF la antibody to the Wells With the immobilized secondary

EXAMPLE 2

cinimide ester of 6-keto-Prostaglandin Fla Was prepared by
reacting With the Water-soluble analog of N-hydroxysuccin
imide (NHS), sulfo-NHS, and the dehydrating agent EDC.

Construction of Plasmids containing Aequorin Mutants. The

Grabarek. Z. a. G., J. Anal. Biochem. 1990, 185. The analyte

gene of a mutant apoaequorin in Which all three cysteines of
the native aequorin Were replaced by serines Was used as a
template for the PCR. A unique mutation Was introduced on

6-keto-Prostaglandin Fla (1 mg/mL) Was alloWed to react
With ~5 mM sulfo NHS and ~2 mM EDC (?nal concentra
tions) for 30 minutes at R.T. The reaction Was quenched by
adding [3-mercaptoethanol to a ?nal concentration of 20 mM.
This NHS ester of the analyte Was then conjugated to
aequorin With bound coelenteraZine in three different mole

the puri?ed apoaequorin gene (Ala 69 to cysteine 69) by
employing PCR site-directed mutagenesis. The oligonucle
otides used for PCR are AQ69-1 and AQ69-2 (see Table 1).

ratios, 1:50, 1:200, and 1:500 of aequorin: 6-keto-PGFla The
conjugates Were passed through a siZe exclusion column in
order to remove any unconjugated NHS ester of 6-keto

20

1) TCTTCTTCTTCTTCTAAGCTTGTCAAGCTTACA
TCAGACTTCGACAACCCAAGA (SEQ ID NO. 1); and 2)

PGFla and any residual reactants or reducing agent. The

fractions Were tested for activity of aequorin by taking 100 ML
of each fraction, then adding 3 ML of 2.36><10_4 M coelentera
Zine and measuring the intensity of light emitted as described
before. The fractions shoWing activity Were combined and

AGAAGAAGMGAGTCGACCAGATCTGG

TACCCGGGAATT (SEQ ID NO. 2).
25

lyophiliZed. The lyophiliZed conjugates Were resuspended in
30 mM Tris-HCl buffer, pH 7.0, containing 2 mM EDTA,
0.15 M NaCl and 1 mg/mL BSA (assay buffer) and stored in
aliquots at —80° C.
Calibration curves Were generated for each of the conju

With the restriction enZymes Hind Ill and Sal 1. Next, the
30

gates (1:50, 1:200, 1:500) by ?rst converting the apoaequorin

containing unique cysteine residues at position 70, 74 and 76

35

luminescence signal Was integrated over a 3 second time

40

45

Expression and Isolation of Aequorin Mutants. For expres
sion of apoaequorin mutant 69 the plasmid pSD 1004 Was
transformed into Bacteria (E. coli, strain JM109). A 2 mL
volume of LB broth containing 100 ug/mL of ampicillin Was
inoculated With a colony of bacteria containing plasmid pSD

reached an absorbance of 0.6 at 600 nm. For induction of

protein expression, 1 M IPTG stock solution Was added such
that the ?nal IPTG concentration in the culture Was 1.0 mM.
The culture Was alloWed to groW for an additional 4.0 h at 37°
C. in the shaker. The cells Were centrifuged for 30 min at 27°

With Wash buffer (30 mM Tris-HCL buffer, pH 7.0, contain
ing 2 mM EDTA, 0.15 M NaCl, and 0.1% TWeen 20) three
times to remove any unbound primary antibody or any
50

C. and pelleted.
The apoaequorin mutant 69 thus expressed Was released

as described earlier for the calibration plot.

from the periplasm using an osmotic shock procedure. The

Dose-Response Curve: A dose-response curve Was generated

for 6-keto-PGFla by simultaneously incubating 100 ML of
6-keto-PGF1a antibody (1:10,000 dilution), 50 ML of differ

site-speci?c mutations.

containing 100 ug/mL ampicillin, and alloWed to groW until it

key anti-sheep lgG. All dilutions Were done in the assay

unbound conjugate. Finally, the light intensity Was measured

above. DNA sequencing Was performed at the Macromolecu
lar Center (University of Kentucky) to con?rm the presence

1004. The cells Were groWn for 17 h at 37° C. in an aerated
shaker. The cell culture Was transferred to 400 mL LB broth

PGFla-aequorin conjugate Were placed simultaneously in
microtiter plates pre-coated With a secondary antibody, don
buffer. The plates Were incubated in dark at room temperature
for 2 h With shaking at 300 rpm. Then the plates Were Washed

digested DNA fragment Was ligated into the plasmid pFLAG
ATS, to yield the pSD1004 vector. The apoaequorin mutants
Were prepared in the same manner (see Table 1) as described

before. Standard solutions Were prepared by serially diluting

period. All points Were obtained in triplicates.
For the binder dilution studies aliquots of 100 ML of differ
ent concentrations of serially diluted anti-6-keto-PGF1OL anti
body, produced in sheep and 50 ML of 1x10‘10 M 6-keto

The DNA obtained by PCR and the vector PFLAG-ATS
Which consists of the gene sequence for the octapeptide

upstream of the multiple cloning site (MCS) Were digested

conjugate to aequorin With coelenteraZine as described
the stock solutions of the conjugates assay buffer. A volume
of 100 ML of these solutions Was placed in a microtiter plate
and the luminescence activity of aequorin Was measured. The

The folloWing tWo primers Were used as outside primers to
introduce the restriction endonuclease site for Hind Ill and
Sal I restriction enZymes:

55

ent concentrations of the serially diluted analyte, 6-keto

pellets Were ?rst resuspended in 40 mL of 10 mM Tris-HCl/
30 mM NaCl, pH 7.5. The cells Were then collected by cen
trifuging for 15 min at 27° C., and Were resuspended in 40 mL

of 33 mM Tris-HCl, pH 7.5. The centrifugation and resuspen

PGF la, and 50 ML of 1 x10“10 M coelenteraZine bound 6-keto

sion steps Were repeated, but this time the cells Were resus

PGFla-aequorin conjugate (1 :500) on microtiter plates

pended vigorously With 40 mL Stage 1 buffer. The resus
pended cells Were incubated at 37° C. for 10 min, With sloW
shaking. The cells Were again collected by centrifuging for 10
min at 27° C. The pellets Were ?nally resuspended rapidly
With vigorous shaking for 10-15 min in 80 mL of chilled
deionized-distilled Water. After centrifuging for 10 min at 4°
C., the supernatant Was collected and lyophiliZed. The lyo
philiZed sample Was dissolved in deioniZed Water and dia

coated With the secondary antibody. The plate Was incubated
in dark at room temperature for tWo hours With shaking at 300
rpm. The plate Was Washed three times With the Wash buffer to
remove any unbound components. The light intensity Was

60

measured as described before.

A dose-response curve for 6-keto-PGF1a in plasma Was

generated by preparing serially diluted standard solutions of
6-keto-PGF1a in human plasma (previously diluted 1:200
times With deioniZed Water) and adding them simultaneously

65

lyZed three times against 30 mM Tris-HCl, pH 7.7, buffer
containing 0.15 M sodium chloride, 2 mM EDTA, and 4 mM

US 7,659,078 B1
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DTT. The dialyZed sample Was then centrifuged for 10 min at

mM EDTA, 0.15 M NaCl and 1 mg/mL BSA (assay buffer)

4° C. to remove any cell membrane fragments. The superna
tant, Which consisted of unpuri?ed protein Was ?ltered With a

and stored in aliquots at —80° C.
EXAMPLE 3

0.2 pm syringe ?lter and Was immediately puri?ed. The
apoaequorin mutants 70, 74 and 76 Were expressed and iso

A comparative study betWeen analysis of 6-keto-PGF1a

lated in the same Way as described above by using bacteria

With and Without extraction from plasma Was carried out. In
order to extract 6-keto-PGF la from plasma, a ?xed volume of
the plasma sample Was ?rst acidi?ed With 2M HCl to pH 3.5.
The sample Was alloWed to stand for 15 min at 4° C., after
Which it Was centrifuged for 2 min to remove any precipitate.
MeanWhile, a C 1 S-reverse phase column Was Washed With 10

containing plasmid pSD 1005, pSD 1006 and pSD 1007

respectively.
Puri?cation of the Apoaequorin Mutants. The proteins Were

puri?ed by using an anti-octapeptide M2 agarose a?inity
column. The column Was equilibrated With 50 mM Tris-HCl,
pH 7.4 containing 150 mM NaCl and 2 mM EDTA (TBS
buffer). The solution containing protein Was loaded on the

mL ethanol, folloWed by 10 mL deioniZed Water. The sample
Was then applied under a slight positive pressure to obtain a
How rate of 0.5 mL/min. The column Was Washed With 10 mL

column and the column Was Washed three times With 15 mL

of Water, folloWed by 10 mL of 15% ethanol and ?nally 10 mL
of hexane. The sample Was eluted using 10 mL of ethyl

of TBS buffer. The proteins Were eluted using 1 mL aliquots
of 0.1 M glycine, pH 3.0, into tubes containing TBS buffer.
The fractions containing the protein and their purity Was

determined by SDS-PAGE using 12.5% polyacrylamide gels,
Which Were developed by silver staining (Pharmacia Biotech,
Uppsala, SWeden). Fractions containing the fusion protein

acetate. Elution Was carried out at a How rate of 2 mL/min.
20

Were pooled together and glucose Was added to a ?nal con

centration of 30 mM folloWed by lyophiliZation. The lyo
philiZed protein Was resuspended in deioniZed distilled Water.
Excess salt Was removed by dialyZing tWice against 30 mM
Tris-HCl, pH 7.4 containing 2 mM EDTA and 2 mM DTT.
The protein concentration Was determined by using the Brad

These samples Were used in the dose response curve per
formed in buffer.
25

30

appropriate dilution factor Was taken into consideration When

calculating the amount of 6-keto-PGFla present in each
35

required time.
Bioluminescence Emission Study. A volume of 10 pL of the

7 normal controls. Written informed consent Was obtained

from all patients; the protocol Was approved by the Institu

glass tube, and the bioluminescence Was measured by inject
ing 100 pL of luminescence triggering buffer (100 mM Tris

HCl, 100 mM CaCl2, pH 7.5). The bioluminescence signal
Was collected at 0.1 second intervals over a 4 second time

period.
45

Luminescence Was triggered by careful addition of 1 .0 mL of

obtained and stored froZen at —20° C., in aliquots until use.
In order to obtain recovery data further analysis of the
50

without turning on lamp or chopper. The spectra Were not

spiked With 5 pg/mL of6-keto-PGF1a and the patient samples

tube to luminescence at different Wavelengths.

Were spiked With 10 pg/mL of 6-keto-PGFla and the samples
55

mL of 1x10‘6 M. aequorin Was alloWed to incubate With
coelenteraZine for 3 h at 4° C. Five-fold excess of a maleim
ide/iodoacetamide derivative of analyte Was alloWed to react

With mutant aequorin for 2 h at RT. The conjugates Were
passed through a siZe exclusion column in order to remove

60

any unconjugated maleimide/iodoacetamide derivative of
analyte. The fractions Were tested for activity of aequorin by
taking 100 pL of each fraction, then adding 3 pL of 2.36><10_4
M coelenteraZine and measuring the intensity of light emitted
as described before. The fractions shoWing activity Were

combined and lyophiliZed. The lyophiliZed conjugates Were
resuspended in 30 mM Tris-HCl buffer, pH 7.0, containing 2

samples Was performed. TWo of the normal plasma samples
and tWo patient plasma samples Were ?rst analyZed using the
assay Without extraction. Then the normal samples Were

corrected for changes in sensitivity of the photomultiplier
Conjugation of Aequorin Mutant to Analyte: A volume of 1

tional RevieW Board at Mount Sinai School of Medicine. Of
the ?ve patients, three Were on chronic intravenous prostacy
clin. All patient samples Were analyZed in the same manner as
the dose response curve in plasma. The samples Were diluted
1:200 times to minimiZe matrix effects and 50 pL of the
sample Was used in the assay. The amount of 6-keto-PGF la in
the samples Was calculated as described before for sample

analysis Without extraction. All plasma samples Were

a 1.0><10—6 M solution of mutant aequorin using a constant

rate syringe pump into 0.5 mL of luminescence triggering
buffer. Emission spectra Were obtained using a Fluorolog-2

spectro?uorometer from Spex Industries (Edision, NJ.)

sample.
For in vivo analysis plasma samples Were obtained from
?ve patients With severe pulmonary arterial hypertension and

mutant proteins at a concentration of 1 ug/mL Was added to a

Bioluminescence Emission Spectra ofApoaequorin Mutants.

manner as the dose-response curve described before. The

amount of 6-keto-PGFla in the samples Was calculated from
the standard dose response curve generated in plasma. The

amount of puri?ed protein in 30 mM Tris-HCl, pH 7.4, buffer
containing 2 mM EDTA and 2 mM DTT Was mixed With a
three time molar excess of coelenteraZine in a glass tube. The
mixture Was brie?y vortexed and then placed on ice for the

The analysis of 6-keto-PGF1a directly in plasma Without
extraction Was performed by diluting the samples 1:200 times
and using 50 pL in the dose-response curve along With 100 pL
6-keto-PGF1a of antibody and 50 pL of 6-keto-PGFla-ae
quorin conjugate. The analysis Was performed in the same

ford protein assay, With BSA as the standard.

Conversion of Apoaequorin Mutants to Photoproteins. A set

The ethyl acetate in the samples Was evaporated under a
stream of nitrogen. The dried samples Were ?rst dissolved in
50 pL ethanol, and then in the same volume of the assay buffer
as that of the plasma sample initially used for extraction.

65

Were used once again in the assay. In each case the samples
Were diluted 1:200 times to minimiZe matrix effects and 50
pL of the sample Was used in the assay. The amount of
6-keto-PGF1a in the samples Was calculated as described

before for sample analysis Without extraction. The samples
Were analyZed in triplicates.
The plasmid containing the cysteine free mutant of
aequorin Was previously constructed in our laboratory. LeWis,
J. C., LopeZ-Moya, J. 1., and Daunert S. Bioconjugale Chem.
2000, 11, 65-70. The cysteine free mutant of aequorin Was
chosen for the development of this assay because it shoWed
enhanced activity as compared to Wild-type aequorin. The
cysteine free mutant of aequorin Was expressed from plasmid
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pSD110. Puri?cation of aequorin Was carried out using an

kept constant at 1x 1 0'10 M, Whereas the antibody concentra

HQH anion exchange column. The fractions containing
bioluminescence activity Were lyophilized With glucose and
later resuspended in deionized Water. SDS-PAGE analysis

tion Was either increased or decreased by a factor of 5. In the

third experiment, the antibody concentration used Was a 1 :10,
000 dilution, and the conjugate concentration Was increased
to 1x10‘9 M. As shoWn in FIG. 2, When a higher antibody

Was carried out to check the ef?ciency of puri?cation. A
single band Was observed at ~20 kDa in the lyophilized frac
tion for pure aequorin. The yield of the protein Was found to

concentration is used, the sensitivity improves but the detec
tion limit is compromised. When a more diluted amount of

be 1.8 mg/L of culture.

antibody is used, the dynamic range narroWs signi?cantly and
the sensitivity is reduced. Finally, When a higher concentra
tion of the conjugate is employed both, the detection limit and
the dynamic range Worsen. Therefore, based on these data,
the optimum antibody dilution for the assay Was determined
to be 1:10,000 and the conjugate concentration to be 1><10_l0
M (FIG. 2). Next, a dose-response curve Was generated by

Before conjugating 6-keto-PGFla to aequorin, the lyo
philized fraction Was dialyzed against bicarbonate buffer to
remove any residual Tris-HCl salt, Which might interfere With

the conjugation. The dialyzed aequorin Was then charged With
3 times molar excess of coelenterazine so that the analyte

Would not conjugate in the coelenterazine binding site, Which
might cause loss in activity of aequorin.
The conjugation method used involved a tWo-step coupling
method using EDC (1-Ethyl-3-(Dimethylaminopropyl) car

simultaneously mixing varying concentrations of free 6-keto
PGFlot, 1><10_lo M of the 1:500 conjugate, and 1:10,000
dilution of the 6-keto-PGF10t antibody and incubating them
in microtiter plates immobilized With the secondary antibody.

bodiimide hydrochloride) and sulfo NHS, Which is a Water

soluble analog of NHS (N -hydroxy succinimide). EDC, a
dehydrating agent, reacts With the carboxyl group of 6-keto

The dose-response curve obtained for 6-keto-PGF10t as
20

PGF la, and forms an amine-reactive unstable, O-acylisourea

PGFIO. and increasing as the concentration of 6-keto-PGF10t
decreases. The Working range of the curve ranges for concen

intermediate of 6-keto-PGFla. NHS reacts With the O-acyli
sourea-intermediate to form an NHS ester to stabilize this

trations of 10,000 pg/mL-l pg/mL. The detection limit for

intermediate. The NHS ester then reacts With the amine

groups on aequorin. The advantage of the tWo-step procedure
is the prevention of the modi?cation of the protein carboxyl

25

groups due to exposure to EDC. Grabarek, Z. a. G., J. Anal.

any possible matrix effects on the performance of the conju
30

method, by increasing the initial molar concentration of the
NHS ester of 6-keto-PGF1OL While keeping the concentration
of aequorin constant. The conjugates Were passed through a
35

In order to study the effect of conjugation on the biolumi
nescence activity of aequorin and to select an appropriate
conjugate concentration for the assay, calibration plots Were

constructed for each of the conjugates (data not shoWn). The
conjugates (1:50, 1:200 and 1:500) could be detected doWn to
1x10‘12 M. A concentration of 1x10‘10 M of the three con
jugates Was selected for the binder dilution study. This con
centration Was loW enough to be able to detect aequorin at loW
levels With high sensitivity and at the same time it shoWed

40
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the do se-response curve in plasma for ?ve consecutive days in
50

coel?cient of variation Was found to be 4.5%. The intra-assay

precision Was determined by doing 4 replicate measurements
55

increased until it reached a concentration after Which there
Was no signi?cant increase. It Was observed that the 1:500

of the same sample. The average coel?cient of variation Was
found to be 1.25%.

Presence of various prostaglandins other than 6-keto
PGFla in the blood can cause non-speci?c binding With the

conjugate shoWed maximum binding therefore, it Was used
for the remaining experiments in the assay. The amount of

and/ or conjugate on the dose-response curve Was also evalu
ated. In the ?rst tWo cases, the conjugate concentration Was

exactly the same manner as described earlier. The percent

coel?cient of variation for samples containing different con
centrations of 6-keto-PGFlw Was calculated. The average

the secondary antibody-coated microtiterplate for 2 h at room
temperature. After Washing the plate to remove any unbound
antibody or conjugate the luminescence Was measured. As the

the background, While keeping the amount of available bind
ing sites to a minimum. The antibody dilution selected for
developing the assay Was 1:10,000 dilution. The effect of
increased or decreased amounts of 6-keto-PGF1a antibody

gate. The detection limit of this dose-response curve Was also
found to be 1 pg/mL and the limit of quantitation Was found
to be 5.11 pg/mL. This demonstrates that even loW levels of
6-keto-PGF1a could be detected in the assay, and also that
aequorin is an excellent label for the detection of biomol

ecules in biological ?uids.
The inter-assay precision Was determined by generating

The next step Was to study the interaction betWeen the

antibody to be used in the assay Was selected such that the
light intensity emitted is suf?cient to measure a signal above

therefore, a loW bioluminescence signal in the solid phase Was
obtained. As the concentration of free-analyte decreases, the
bioluminescence intensity reaches a maximum since most of

the binding sites on the antibody are occupied by the conju

anti-6-keto-PGFla antibody and the conjugates. For this,

concentration of antibody increased the light intensity

Was almost identical to that obtained for 6-keto-PGFla in
buffer. According to this dose response curve, and as expected
of 6-keto-PGF la at high concentrations of free 6-keto-PGF1a

most of the binding sites are occupied by 6-keto-PGFlw and

much higher activity than the background.
binder-dilution curves Were generated for all three conjugates
as shoWn in FIG. 1. The 6-keto-PGFla antibody Was incu
bated With a concentration of 1x10“10 M of the conjugates in

gate or the binding capabilities of the 6-keto-PGF1a antibody
in plasma. The assay Was, therefore, performed in 1:200
diluted human plasma spiked With known concentrations of

6-keto-PGFla. The dose-response curve obtained (FIG. 4)

size exclusion column to remove any unconjugated ester of

6-keto-PGF1a and unreacted [3-mercaptoethanol. They Were
then lyophilized and later resuspended in the assay buffer.

6-keto-PGF10t Was determined to be 1 pg/mL, Which corre

sponds to a 2x10‘12 M concentration of 6-keto-PGF10t.
Since the goal Was to detect 6-keto-PGF10t in plasma, it
Was necessary to validate this assay in plasma and to study

Biochem. 1990, 185. The reaction is quenched by a thiol

containing compound like [3-mercaptoethanol. Three differ
ent conjugates Were prepared (1 :50, 1:200, 1:500) using this

depicted in FIG. 3, is sigmoidal in shape, With the lumines
cence intensity being loWer at high concentrations of 6-keto

6-keto-PGF1a antibody and interfere With the detection of
60

6-keto-PGFlw giving extremely high values of 6-keto
PGFla. Therefore, it becomes important to con?rm that the
amount of 6-keto-PGF la obtained from our assay is only due
to 6-keto-PGF1a and no other prostaglandin. The cross-reac
tivities of other prostaglandins similar in structure to 6-keto

65

PGFla Were determined by preparing standard solutions of
the compounds in the assay buffer ranging from 100,000 to
100 pg/mL and using them in this assay for 6-keto-PGFla.
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The measured 6-keto-PGFla concentration at 50% B/BO Was
then calculated. The percent cross-reactivities Were calcu
lated by comparison of measured cross-reactant concentra

measured using the standard dose response curve obtained in

plasma by diluting plasma of a normal subject (1:200) to
measure the amount of 6-keto-PGFla. It Was observed that

tion and the actual concentration (known amount) of the
cross-reactant in the sample (Table 1). It must be noted that

the levels of 6-keto-PGF1a increased With increase in the
pro stacyclin dose. Three normal control samples Were used to
produce the standard dose-response curves, and the curves
Were found to be similar. The values of 6-keto-PGF1a in the
samples of patients obtained With each of the standard curves
Were also similar. Table 2 shoWs the 6-keto-PGF1a values in

the pro staglandins occur at different times in the arachidonic

acid pathWay and in different concentrations. Also, 2,3 -dinor
6-keto-Prostaglandin F la is found in urine and does not occur

in plasma, hoWever since it is the immediate metabolite of
6-keto-PGF1a We decided to analyze the cross-reactivity of

normal and patients samples in vivo. Plasma samples of the
normal subjects Were used to produce standard dose-response

2,3-dinor-6-keto-Prostaglandin F la as Well. From the table it

is clear that the prostaglandins do not shoW any signi?cant
amount of cross-reactivity. This indicates that the assay is
speci?c only for 6-keto-PGF1a and there is no interference
from other prostaglandins, Which might be present in the
plasma samples. The assay can, therefore, be used to measure

curves and values of 6-keto-PGF1a in patient samples Were
obtained using those curves. The measurements Were per

formed in triplicates. The results are shoWn in Table 3.

6-keto-PGF1a directly from plasma.

TABLE 3

6-keto-Prostaglandin F1

TABLE 1
Prostacyclin Dose

concentration measured
Without extraction

Standard

(ngkg/min)

(ng/ml)

Deviation

i

1.7

0.01

28.5
10
8
0
0

9.9
6.7
4.1
2.2
1.5

0.2
0.05
3.1
1.5
0.05

20

Oligonucleotide sequence of primers

Plasma Sample

AQ69-1 GCCTTCTTCGGAGGAEGGAATGAAATAT Ala69-Cys69
Average of3

(SEQ ID NO. 3)

AQ69-2 ATATTTCATTCC?TCCTCCGAAGAAGGC
(SEQ ID NO. 4)

AQ70-1 GCTEATGAAATATGGTGTGGAAACTGAT Gly70-Cys70
(SEQ ID NO. 5)

AQ70-2 ATCAGTTTCCACACCATATTTCAT?AGC

normal samples

Ala69-Cys69

Gly70-Cys70

(SEQ ID NO.6)

PPH
25 PPH
PPH
PPH
PPH

Patient 1
Patient 2
Patient 3
Patient 4
Patient 5

AQ74-1 GCTGGAATGAAATATTGEGGAAACTGAT Gly74-Cys74
(SEQ ID NO. 7)

AQ74-2 ATCAGTTTCCAC?ATATTTCATTCCAGC

Gly74-Cys74

30

(SEQ ID NO. 8)

EXAMPLE 5

AQ76-1 ATGAAATATGGTGTGEACTGATTGGCCT Glu76-Cys76
(SEQ ID NO. 9)

AQ76-2 AGGCCAATCAGT?CACACCATATTTCAT

Glu76-Cys76

(SEQ ID NO. 10)
35

EXAMPLE 3

Cross-reactivities of related prostaglandins Were measured

by using varying concentrations of 50 ML of the cross reactant

40

in the dose response curve instead of 6-keto-PGF10L. The
percent cross-reactivities Were calculated at 50% B/BO. The
results are shoWn in Table 2.
45

TABLE 2

In order to verify the concentration of 6-keto-PGF1a
obtained from plasma using the assay of the present inven
tion, 6-keto-PGF1a Was extracted from the plasma samples of
7 normal subjects and the 5 PPH patients using the C 18-Sep
Pak columns, and these values Were compared With the values
obtained When plasma samples Were used directly in our
assay Without extraction. In the extraction method, the
6-keto-PGF1a Was obtained in the ethyl acetate fraction. All
ethyl acetate Was evaporated under N2 and the dried 6-keto
PGFla Was dissolved ?rst in ethanol folloWed by the assay
buffer. This 6-keto-PGF1a Was used in the assay performed in

Average Standard

buffer. The concentrations of 6-keto-PGF1a obtained using
the aequorin assay in plasma samples, Without pretreatment

Percent Bound

Deviation

Were observed to be highly correlated With the measured

100%
5.4%
3.41%
0.45%

1.71
4.65
3.21

2,3-dinor-6-keto-Prostaglandin P1
Prostaglandin D2
Prostaglandin E1

10.1%
7.75%
6.75%

5.78
2.11
3.87

6,15-diketo-13,14-dihydro-

1.83%

0.92

Analyte

6-keto-Prostaglandin F1
Prostaglandin 131
Prostaglandin F2
13,14-dihydroxy-15-keto-

6-keto-PGF1a after extraction. The equation for the straight
50

1.01

Prostaglandin F1
55

line can be given as y:0.79x+418, r:0.988, n:12.
Further in vivo analysis Was performed in order to deter

mine the recovery of 6-keto-PGF1a from samples using this
assay. TWo of the normal plasma samples and tWo patient
plasma samples Were ?rst analyZed using the assay as
described before and determining the concentration of

6-keto-PGF1a present in the samples by using the standard

Prostaglandin F 1

curve in 1:200 diluted plasma. A knoWn amount of 6-keto
EXAMPLE 4

60

PGFla Was spiked into the samples and the samples Were
analyZed once again to determine the concentration of 6-keto
PGFla. Percent recovery data Were obtained using the con

In vivo sample analysis Was performed With the present
assay. The PPH patients and control samples Were provided
by Dr. Michael Poon of the Mount Sinai Pulmonary Hyper
tension Program. Five PPH patient plasma samples Were
diluted (1:200) times With buffer and used directly in the
assay. The concentration of 6-keto-PGF1a in the samples Was

centration of 6-keto-PGF1a in unspiked samples and the con
centration obtained after spiking. It is clear from the data

(Table 3) that this assay for 6-keto-PGFla gives recoveries
65

Within the range error. Percent recovery data of normal

samples and patient samples are shoWn in Table 4. The mea
surements Were performed in triplicate.

US 7,659,078 B1
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TABLE 4

Prostacyclin
Dose

Subject

Amount of

6-keto-PGF 1

6-keto-PGF 1

6-keto-PGFl

spiked into
salnples

found in spiked
salnples

Percent

found in unspiked
Weight
samples

Concentration of

(ngkg/min)

(kg)

(ngml)

(ngml)

(ng/ml)

Recovery

0
0

i
i

2.05
2.91

5
5

7.53
8.01

106.8%
109%

10
28.5

95
78.5

8.32
9.96

10
10

Norrnal salnple
Norrnal salnple

PPH patientl
PPH patient2

Concentration of

20.2
21.7

measuring them in the biological matrix Without requiring

In conclusion, this immunoassay, is the ?rst direct assaying

technique for quanti?cation of plasma 6-keto-PGF1a Without

115%
117.4%

15

any pre-treatment of the biological ?uids. This assay may

the process of extraction. The 6-keto-PGF1a concentrations

alloW high throughput analysis of the levels of plasma pros

obtained from patient samples by extraction and Without
extraction shoW good correlation. In addition, the antibody

tacyclin in patients With primary pulmonary hypertension and
the clinical implications of various levels of plasma prosta
cyclin in the pathogenesis and clinical management of this

employed for the assay, and hence the assay itself, does not

shoW signi?cant binding to other related prostaglandins.
Therefore, the possibility of obtaining falsely high values of
6-keto-PGF1a due to the presence of other similar prostag
landins is eliminated. The assay has a Wide Working range,
and a loW detection limit of 1 pg/mL, Which enables the
measurement of the creation of distribution curves of plasma
prostacyclin levels in normal and disease states. This assay

also characterizes the application of aequorin in quanti?ca
tion of important components present in the body by directly

20

devastating disease.
The following abbreviations are used herein: 6-keto

PGFla: 6-keto-ProstaglandinFla; PPH: Primary Pulmonary
Hypertension; EDC: 1-Ethyl-3-(Dimethylaminopropyl) car
25

bodiimide hydrochloride; NHS: N-hydroxysuccinimide;
BSA: Bovine plasma albumin; SDS-PAGE: Sodium dodecyl

sulfate-Polyacrylamide gel electrophoresis; Tris: Tris (hy
droxymethyl)amino methane; EDTA: ethylenediaminetet
raacetic acid.

SEQUENCE LISTING

SEQ ID NO 1
LENGTH: 54
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Artificial sequence of unknown origin used as
outside primers to introduce the restriction endonuclease site for
Hind III and Sal I restriction enzymes

<400> SEQUENCE:

l

tcttcttctt cttctaagct tgtcaagctt acatcagact tcgacaaccc aaga

54

SEQ ID NO 2
LENGTH: 39
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Artificial sequence of unknown origin used as
outside primers to introduce the restriction endonuclease site for
Hind III and Sal I restriction enzymes

<400> SEQUENCE: 2

agaagaagaa gagtcgacca gatctggtac ccgggaatt

39

SEQ ID NO 3
LENGTH: 30
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Artificial sequence of unknown origin used for
PCR

<400> SEQUENCE: 3

US 7,659,078 B1
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—cont inued

gccttcttcg gaggatgtgg aatgaaatat

<2ll> LENGTH:

3O

30

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Artificial sequence of unknown origin used for
PCR

<400> SEQUENCE: 4
atatttcatt ccacatcctc cgaagaaggc

<2ll> LENGTH:

3O

30

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Artificial sequence of unknown origin
<400> SEQUENCE: 5

gcttgcatga aatatggtgt ggaaactgat

<2ll> LENGTH:

3O

30

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Artificial sequence of unknown origin
<400> SEQUENCE: 6

atcagtttcc acaccatatt tcatgcaagc

<2ll> LENGTH:

3O

30

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Artificial sequence of unknown origin
<400> SEQUENCE: '7

gctggaatga aatattgtgt ggaaactgat

<2ll> LENGTH:

3O

30

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Artificial sequence of unknown origin
<400> SEQUENCE: 8

atcagtttcc acacaatatt tcattccagc

<2ll> LENGTH:

3O

30

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Artificial sequence of unknown origin
<400> SEQUENCE: 9

atgaaatatg gtgtgtgcac tgattggcct

<2lO> SEQ ID NO 10
<2ll> LENGTH: 30
<2l2> TYPE: DNA

3O

US 7,659,078 B1
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20
—cont inued

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Artificial sequence of unknown origin
<400> SEQUENCE: lO

aggccaatca gtgcacacac catatttcat

30

(5) correlating the light intensity of the bound 6-keto
PGFIOL conjugate With the amount of the prostaglandin
in the plasma sample.

What is claimed is:
1. A method of determining amount of prostaglandin in a

plasma sample comprising:
(1) providing a plasma sample from a patient in contact

15

With a surface coated With an anti-immunoglobulin anti

amount in the sample.
3. The method of claim 1 Wherein the plasma sample is
obtained from a patient receiving intravenous prostaglandin

body;
(2) incubating the plasma sample With an effective amount
of an anti-6-keto-prostaglandin Fla (6-keto-PGFla)

antibody, Wherein the anti-immunoglobulin antibody

20

4. The method of claim 1 Wherein concentration of said

5. A kit for measuring prostacyclin in plasma comprising:
(1) an anti-6-keto-prostaglandin Fla (6-keto-PGFla) anti

conjugate comprising 6-keto-PGF1a covalently bound
to an aequorin mutant,
25

tions for all three cysteine residues as present in Wild

6-keto-PGF lot-antibody; and

(3) a conjugate comprising 6-keto-PGF1a covalently

mutant further comprises a single cysteine residue sub
stituted at amino acid position 69 (Ala69 QCys), 70

bound to an aequorin mutant;
30

type aequorin (CysQSer), Wherein said aequorin

Wherein the 6-keto-PGF1a is coupled to the aequorin

mutant further comprises a single cysteine residue sub
stituted at amino acid position 69 (Ala69QCys), 70

mutant via reaction With the sulihydryl group of the

(3) removing any unbound anti-6-keto-PGFlot-antibody
and said conjugate following incubation;
(4) measuring light intensity of the 6-keto-PGF1a conju
gate bound to the anti-immunoglobulin antibody; and

Wherein said aequorin mutant comprises serine substitu
tions for all three cysteine residues as present in Wild

and

single cysteine;

body;
(2) an anti-immunoglobulin antibody that binds to the anti

type aequorin (Cys—>Ser), Wherein said aequorin
(Gly70 QCys), 74 (Gly74 aCys) or 76 (Glu76 QCys),

therapy.
conjugate in the assay is about l><l0_lo M.

binds to the anti-6-keto-PGFlot-antibody, and With a

Wherein said aequorin mutant comprises serine substitu

2. The method of claim 1 Wherein the amount of the pros

taglandin in the sample is correlated With prostacyclin

35

(Gly70 QCys), 74(Gly74QCys) or 76 (Glu76—>Cys),
and Wherein the 6-keto-PGFla is coupled to the
aequorin mutant via reaction With the sulihydryl group

of the single cysteine.
*

*

*

*

*

